We used coding and noncoding polymorphisms evenly spaced across the ABCB1/MDR1 gene to perform association analysis in Slovenian patients with inflammatory bowel diseases and to obtain haplotype structure and patterns of linkage disequilibrium (LD) in the MDR1 gene. A disease association study was performed in 307 IBD patients, including 144 patients with ulcerative colitis (UC) and 163 patients with Crohn's disease (CD), and 355 healthy controls. Here we report an association between MDR1 alleles, polymorphisms and haplotypes and refractory CD patients, who do not respond to standard therapy, including patients who develop fistulas. We also report an association with UC and MDR1 polymorphisms in a Slovenian population. Haplotypes significantly associated with diseases were defined by single-nucleotide polymorphisms (SNPs) in exons 12 (1236 C4A), 21(A893S), and 26 (3435 C4T). In addition, two intronic SNPs in LD with the disease haplotype, one in intron 13 (rs2235035) and another in intron 16 (rs1922242), were significantly associated with refractory Crohn (P ¼ 0.026, odds ratio (OR) 2.7 and P ¼ 0.025, OR 2.8, respectively), as well as with UC (P ¼ 0.006, OR 1.8 and P ¼ 0.026, OR 1.9, respectively). Our results suggest that MDR1 is a potential target for therapy in refractory CD patients and in patients with UC.
Introduction
The human inflammatory bowel diseases (IBD) are usually classified into Crohn's disease (CD) and ulcerative colitis (UC). UC is manifested as chronic inflammation in the colon and rectum, while CD can affect the whole gastrointestinal tract. More than 20% of patients with active luminal CD and more than 50% of patients with fistulas fail in standard therapy with antibiotics, corticoids, and immunomodulators. 1 IBD are complex diseases in which environmental, microbial, and genetic factors play a role. Mapping studies in IBD families suggest that several genes might be associated with susceptibility for IBD. The susceptibility loci include 16p12-q13 (IBD1), 12p13.2-q24.1 (IBD2), the major histocompatibility region on chromosome 6 (IBD3), 14q11-12, and 7q. 2 Recently, mutations in the NOD2 gene located on 16p were associated with CD but not with UC. 3, 4 P-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter 5 was initially identified as a protein responsible for multidrug resistance in cancer cells. P-gp is encoded by the ABCB1/MDR1 gene located on chromosome 7q. P-gp is expressed physiologically in several human tissues, suggesting that it has multiple functions. The highest levels of P-gp are found in epithelial cells of the kidney, liver, pancreas, and colon, in cells forming the blood/brain barrier and in lymphocytes. P-gp plays a role in the secretion of toxic compounds, 6 in apoptosis, 7 and in the immune response. 8 The mouse knockout (Mdr1aÀ/À) model suggests a role of P-gp in IBD. 9 Decreased expression of P-gp was identified in IBD patients as compared to controls. 10 Recently, potential functional naturally occurring single-nucleotide polymorphisms (SNPs) within the MDR1 gene were identified in healthy individuals associated with altered duodenal P-gp expression and drug uptake 11 and in colorectal cancer patients associated with lymphoid infiltration in tumors. 12, 13 The extended pharmacogenomics, functional, and complex disease association studies, focused mainly on common synonymous C3435 T polymorphism in exon 26, initially associated with lower P-gp functional expression and higher plasma levels of digoxin after oral admission, 11 provided controversial results, and suggested that C3435 T poly-morphisms might be in linkage disequilibrium (LD) with other functional SNPs. [14] [15] [16] Haplotype analysis in different healthy populations indeed suggested strong LD of the C3435T SNP with many SNPs across the whole region of MDR1 gene. 17, 18 More recently, the C3435T polymorphism was associated with UC, 19 but this association was not confirmed in other studies. 20 Although population differences and selection of control group for disease association study 21 could play a role in this discrepancy, it is possible that results would be more consistent if an association study was performed with functional SNP(s).
In this study, we performed a systematic mutational analysis of the complete coding, the intron/exon boundary, and promoter region of the MDR1 gene in Slovenian patients with IBD. In addition, we genotyped frequent intron polymorphisms to perform association analysis using evenly spaced coding and noncoding polymorphisms across the entire MDR1 gene and to obtain the LD structure of the MDR1 gene.
Results
Using single-strand conformational analysis and subsequent sequencing, we have screened for mutations in the complete coding, intron/exon boundaries and the promoter region of the MDR1 gene in 124 patients with IBD, including 50 patients with UC, 50 patients with CD responding to standard treatment, and 24 patients with refractory CD. We have identified a nonsynonymous substitution in exon 28 (E1144K), in a patient with UC. We have also identified 10 common polymorphisms that we have previously reported in Slovenian healthy controls and in patients with colorectal cancer.
12, 13 We developed 5 0 nuclease assays for high-throughput genotyping of three frequent coding polymorphisms, two rare noncoding polymorphisms, one in the promoter (SNP2) and another in an intron (SNP3), both previously suggested to have functional significance, 12, 13 as well as five additional frequent intron polymorphisms. These 10 SNPs were typed in 327 IBD patients and 355 healthy controls. The allele frequencies and haplotype structures are described in Tables 3 and the p-values for disease  association are described in Tables 4, 5 and 6. Two polymorphisms, one in intron 13 (SNP7) and another in intron 16 (SNP8), showed significant associations with refractory Crohn (P ¼ 0.0143 and 0.0245, respectively) as well as with UC (P ¼ 0.0053 and 0.0094, respectively, Tables 4 and 5 ). Both polymorphisms were B5 kb apart and were in almost complete LD (D 0 ¼ 0.98, r 2 ¼ 0.74, Figure 1 ). The frequencies of SNP7 (C4T) and SNP8 (A4T) were lower in UC (0.315 and 0.382) and We also compared the frequency of genotypes between patients and controls ( Table 5 ). Carriers of SNP7 T allele (genotypes TT and CT) and SNP8 T allele (genotypes TT and TA) were found more frequently among refractory CD patients (P ¼ 0.026, odds ratio (OR), 2.7 and P ¼ 0.025, OR 2.8, respectively) and UC patients (P ¼ 0.006, OR 1.8 and P ¼ 0.026, OR 1.9, respectively) than in controls.
There were 41 different haplotypes defined by the 10 SNPs in the 120 kb MDR1 gene region and the 12 most frequent haplotypes defined almost 90% of all chromosomes (Table 3) .
However, because of the small number of patients in some disease groups, we used only the most significant SNPs to estimate haplotypes for statistical analysis in patients and controls. Using SNPs 7, 8, and 9, we could estimate seven out of eight possible haplotypes and the four most frequent haplotypes represented more than 98% of all chromosomes (Table 6) . We compared the frequency of individual carriers for the certain haplotype vs noncarriers. The most frequent haplotype H1 (C-A-T) defined by SNPs 7, 8, and 9 was found at a higher frequency in UC patients (0.743) as compared to controls (0.64), and was thus associated with susceptibility to UC (P ¼ 0.027, OR 1.7, 95% CI, 0.392-0.930). The second most frequent haplotype H2 (T-T-G) defined by SNPs 7, 8, and 9 was found at lower frequency in UC patients (0.52) and proctitis (0.44) than in controls (0.64), and was thus protective against UC (P ¼ 0.027, OR 1.7, 95% CI, 0.392-0.930) and proctitis (P ¼ 0.017, OR 2.2, 95% CI 1.158-4.307).
Using SNPs 6, 9, and 10, we could estimate all eight possible haplotypes and the three most frequent haplotypes represented more than 95% of all chromosomes ( Table 6 ). The second most frequent haplotype H2 (T-T-T) defined by three susceptible alleles was associated with higher risk for UC (P ¼ 0.024, OR 1.6) and refractory CD (P ¼ 0.044, OR 3.1). Using SNPs 6, 7, 8, 9, and 10, we could estimate 15 different haplotypes out of 32 possible and the five most frequent represented more than 94% of all chromosomes. The most frequent haplotype H1 (T-C-A-T-T) was associated with higher risk for UC (P ¼ 0.038, OR 1.6) (Tables 1-6).
To assure that the phenotypically homogeneous group of refractory Crohn patients is not otherwise genetically biased, we genotyped 21 SNPs from 13 different genes, including some IBD candidate genes and randomly selected genes, and found no significant difference in the frequency of these SNPs between refractory CD patients and controls (Figures 2 and 3 ). MDR1 polymorphisms in Crohn disease and ulcerative colitis U PotoWnik et al 533
Discussion
Our study reports an association between polymorphisms in the multidrug resistance 1 (MDR1) gene coding for P-glycoprotein (P-gp), and refractory CD patients with severe forms of CD, which develop fistulas and do not respond to standard therapy. Those patients fulfilled strict criteria to be enrolled into treatment with antibody against TNF-a. In contrast to many other studies that focused on a limited number of polymorphisms, mainly on polymorphisms in exons 21 and 26, we included frequent intron polymorphisms spanning the whole gene region in our disease association study to define the patterns of LD and haplotypes across the gene. Haplotype analysis in patients and controls revealed a complex pattern of disease-associated alleles. We found haplotype defined by T-T-T alleles from coding SNPs 6 (exon 12), 9 (exon 21), and 10 (exon 26) significantly associated with higher risk for refractory CD (P ¼ 0.044, OR 3.1) and UC (P ¼ 0.026, OR 1.6), although using each of these SNPs separately resulted in association only at the border of significance (Tables 4 and 5 ). Our study thus confirmed the advantage of haplotype analysis vs analysis of single polymorphisms in complex diseases.
Using only the polymorphism in exon 26 (3435 C4T), an association with UC but not CD was initially described and further confirmed in a German population, 19 ,21 but was not confirmed in two other European populations 20 and in a North American cohort. 22 Brant et al, 22 however, reported association between exon 21 (A893S) and IBD.
In addition, we found two intronic SNPs, one in intron 13 (rs2235035) and another in intron 16 (rs1922242), in LD with the disease haplotype T-T-T defined by SNPs 6, 9, and 10 (Table 4, Figure 1 ), as most significantly associated SNPs with refractory Crohn (P ¼ 0.026, OR 2.7 and P ¼ 0.025, OR 2.8, respectively), as well as with UC (P ¼ 0.006, OR 1.8 and P ¼ 0.026, OR 1.9, respectively). The minor alleles from intronic SNPs 7 and 8 were found at a lower frequency in patients than in the controls and were mainly associated with protective haplotypes (Table 6) . It is therefore possible that combined haplotype analysis with SNPs 7 and 8 and coding SNPs 6, 9, and 10 did not further improve the significance of association, while minor alleles from coding SNPs 6, 9, and 10 were on the other hand associated with disease-susceptible haplotypes. It would be of interest to analyze SNP 7 and 8 in other diseases which have shown association with the SNP in exon 26, for instance, refractory epilepsy 23 and particularly those diseases where the initial association was not confirmed in independent studies, such as HIV infection. 24, 25 We also believe that including intronic SNPs 7 and 8 and haplotypes defined by these two SNPs in analysis of P-gp functional expression might help to better understand the functional consequences of MDR1 polymorphisms. Uwai et al 26 suggested intron 16 poly- MDR1 polymorphisms in Crohn disease and ulcerative colitis U PotoWnik et al 535 morphism (SNP8 in our study)-dependent downregulation of P-gp expression in the kidney cortex during tumor development. However, the expression and functional data to date are mainly available for coding SNPs in exons 21 and 26. [14] [15] [16] Interestingly, several studies suggest increased P-gp expression in patients with refractory CD 27 and a physiological role for P-gp in glucocorticoid transport and protection against glucocorticoid-induced apoptosis of T-lymphocytes (reviewed in Farrell and Kellcher 28 ). Since we did not see any significant correlation with diseases and SNPs upstream from exon 12 and downstream from exon 21, it is most likely that there are unidentified functional variant(s) in the 18 kb gene 17, 18 and confirmed in our study, it is still possible that one or even more functional SNPs are in other regions of the gene and LD with SNPs 7 and 8. We found only a weak association between physical distance and LD, for instance there was no LD between close SNPs 8 and 10, but there was strong LD between distant SNPs 1 and 10 ( Figure 1) .
Polymorphism c.1-81delG (Figure 2 , cDNA accession number NM000927) remains so far unique to the Slovenian population, and to the best of our knowledge the only germline insertion/deletion variation identified in the MDR1 gene. We confirmed this polymorphism with three independent methods, SSCP, fragment analysis, and sequencing. The role of rare or so far even unique MDR1 mutations that alter the conserved amino acids is unclear. In this study, we report the E1144 K mutation in exon 26 in a patient with chronic proctitis, suggesting that rare mutations may play a minor role in IBD. We previously identified G1265S in exon 28 in a patient with CRC. 12, 13 Neither of these two mutations was additionally identified in any other CRC or IBD patient nor in 355 healthy individuals. Interestingly, N183S in exon 7, S1140T in exon 26, 29 P103L in exon 5, and Q1107P in exon 26 were all identified in apparently healthy individuals. Further studies of large cohorts of patients and controls and functional studies are needed to see if these mutations are neutral rare variants rather than disease-relevant mutations.
In conclusion, we identified haplotypes and two MDR1 polymorphisms associated with IBD, which could be relevant to MDR1 association studies with complex diseases. Analysis of MDR1 functional polymorphisms in IBD patients might predict individuals at risk for UC and might help to predict CD patients not responding to standard therapy, thus suggesting more appropriate treatment in these patients, including MDR1 as a potential therapy target. Our results also support a potential role of P-gp in the immune response and supports the idea of multiple physiological functions for P-gp.
Materials and methods

Patients and DNA isolation
The DNA was isolated from paraffin-embedded biopsy sections from Slovenian patients with verified chronic inflammation. There were 139 patients with CD, 144 patients with UC, including 39 patients with inflammation restricted to rectum (proctitis), and 30 unclassified IBD patients. There were 53% male and 47% female patients. The age of these patients ranged from 28 to 91 years. DNA was isolated after tissue digestion using standard phenol/chloroform extraction and ethanol precipitation. MDR1 polymorphisms in Crohn disease and ulcerative colitis U PotoWnik et al 537 DNA was isolated from the blood of 24 patients with refractory CD, who failed standard therapy with antibiotics, corticoids, and immunosuppresants. These patients were enrolled in treatment with anti-TNF alpha (Inflaximab) according to strictly defined criteria. The inclusion criteria for active luminal disease comprised: moderately to severely active CD (11 patients) not adequately responding to prior conventional treatment with 5-aminosalicylates 4.5 g/day given for at least 2 months, antibiotics (metronidazole 1.2 g/day and/or ciprofloxacine 1 g/day) given for at least 1 month, 6-methyl-prednisolone 42 mg/day given for at least 2 months, and azathioprine (AZA) 2.5 mg/kg/day given for at least 6 months. The activity of the disease was evaluated by CD activity index (CDAI). 30 The mean CDAI score for the group was 280 (range 180-320).
The following inclusion criteria were used for fistulizing disease: single or multiple enterocutaneous draining fistulas occurring as a complication of CD (13 patients), with no prior response to standard treatment with metronidazole 0.8 g/day and/or ciprofloxacine 1 g/day given for at least 2 months, and AZA 2.5 mg/kg/day given for at least 6 months.
Exclusion criteria for the study were: other complications of CD (eg symptomatic strictures or stenosis, abscesses, previous proctocolectomy or total colectomy), a history of allergy to murine proteins, a serious infection in the previous 3 months, and prior treatment with anti-TNF-a medication.
Control samples
To determine the potential pathogeneity of MDR1 alterations, we compared the frequency of detected polymorphisms in IBD patients and 355 unrelated unaffected blood donors. All IBD patients and unaffected blood donors were Caucasians.
MDR1 mutational screening. We designed primers to amplify all 28 exons and upstream promoter based on known sequences: GenBank accession numbers: AC002457 and AC005068. Primer sequences for PCR amplifications and lengths of resulting PCR products are listed in Table 1 . More details for reaction conditions are available at upotocnik@ncifcrf.gov. For mutational analysis of the MDR1 gene, we used nonisotopic conformation analysis. Prior to conformation analysis, all exons and exon/intron boundaries of MDR1 gene were amplified (10 min at 951C followed by 35 cycles: 30 s at 951C, 30 s at 551C, 30 s at 721C, and 7 min at 721C) in 10 ml PCR reaction containing 10-100 ng purified genomic DNA, 200 mM each primer, 200 mM each deoxynucleoside triphosphate, 1.0-3.0 mM MgCl 2 , 1Â PCR buffer, and AmpliGold polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). In all, 3 ml of PCR product was mixed with 10 ml of 95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol, 20 mM NaOH, and 3 ml of mixture were heated to 901C for 2 min and then loaded on polyacrylamide gel and electrophoresed in a cold room (41C) for 12 h at 25 W and silver stained. Sequencing was performed with BigDye Terminator Cycle Sequencing Ready Reaction Kit and an ABI310 sequencer (Perkin-Elmer Cetus, Norwalk, CT, USA).
Genotyping of MDR1 polymorphisms
The description of MDR1 polymorphisms and genotyping assays is given in Table 2 . For genotyping, we used the TaqMan allele discrimination assay (Applied Biosystems). For PCR amplification we used ABI buffer, and cycling conditions included initial denaturation at 951C for 10 min, followed by 40 cycles of 951C for 15 s and 621C for 1 min. Reactions were read on an ABI Sequence detection system HT 7900.
A 1 bp deletion in intron 1b (SNP) was genotyped using PCR amplification with a fluorescent-labelled primer and fragment analysis performed on ABI 3700. Genotypes were determined with Genotyper 3.0 software.
Haplotype structure and LD analysis Haplotypes were estimated using the expectation-maximization algorithm. 31 LD between SNP pairs was estimated using Lewontin's coefficient (D 0 ) and Pearson's correlation (r   2   ) . 31, 32 The LD patterns were calculated using Haploview program (http://www.broad.mit.edu/ personal/jcbarret/haplo/index.php). MDR1 polymorphisms in Crohn disease and ulcerative colitis U PotoWnik et al
Statistical analysis
Fisher's exact test using the software package SPSS 11.0 was calculated to compare allele frequencies between patients and controls. In all tests, two-sided P-values of less than 0.05 were considered to indicate statistical significance.
